Judge Tosses Neurocrine’s Suit Over Spruce Hormone-Drug Patent

Neurocrine Biosciences Inc. failed to allege any actual dispute in its lawsuit accusing Spruce Biosciences Inc. of threatening litigation over a patent Neurocrine said endangered its $38,333-a-month hormone disorder drug Crenessity, a federal judge ruled, dismissing the case.

“Like Mills Lane, federal courts referee real fights, not manufactured spats,” Judge Joshua D. Wolson wrote in an opinion issued Monday in the US District Court for the District of Delaware, referencing the late Nevada judge and boxing referee. Wolson dismissed the declaratory-judgment suit for lack of subject matter jurisdiction less that five months after Neurocrine sued to protect the drug, which ...